A share price of Resmed Inc [RMD] is currently trading at $273.37, up 2.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RMD shares have gain 7.52% over the last week, with a monthly amount glided 7.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Resmed Inc [NYSE: RMD] stock has seen the most recent analyst activity on July 15, 2025, when RBC Capital Mkts upgraded its rating to a Outperform but kept the price target unchanged to $294 for it. Previously, Morgan Stanley started tracking the stock with Overweight rating on March 19, 2025, and set its price target to $280. On March 19, 2025, Morgan Stanley initiated with a Overweight rating. Goldman started tracking the stock assigning a Buy rating. Piper Sandler initiated its recommendation with a Neutral and recommended $252 as its price target on January 10, 2025. Stifel started tracking with a Hold rating for this stock on December 13, 2024, and assigned it a price target of $250. In a note dated September 24, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $280 on this stock.
Resmed Inc experienced fluctuations in its stock price throughout the past year between $196.43 and $268.65. Currently, Wall Street analysts expect the stock to reach $265 within the next 12 months. Resmed Inc [NYSE: RMD] shares were valued at $273.37 at the most recent close of the market. An investor can expect a potential drop of -3.06% based on the average RMD price forecast.
Analyzing the RMD fundamentals
Trailing Twelve Months sales for Resmed Inc [NYSE:RMD] were 5.02B which represents 7.92% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.25 and Total Capital is 0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 269.98 points at the first support level, and at 266.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 275.07, and for the 2nd resistance point, it is at 276.77.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Resmed Inc [NYSE:RMD] is 3.41. As well, the Quick Ratio is 2.49, while the Cash Ratio is 0.99. Considering the valuation of this stock, the price to sales ratio is 7.98, the price to book ratio is 7.24 and price to earnings (TTM) ratio is 30.69.
Transactions by insiders
Recent insider trading involved Farrell Michael J., Chief Executive Officer, that happened on Jul 07 ’25 when 8009.0 shares were sold. Officer, Farrell Michael J. completed a deal on Jul 07 ’25 to buy 8009.0 shares. Meanwhile, Director FARRELL PETER C sold 945.0 shares on Jul 02 ’25.
